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Proteinuria, high serum creatinine, and reduced glomerular
filtration rate (GFR) have been associated with increased
mortality from cardiovascular disease (CVD) and all causes.
However, the combined effect of proteinuria with serum
creatinine and GFR on CVD or all-cause mortality has not
been well investigated. We conducted a 10-year prospective
cohort study of 30 764 men and 60 668 women aged 40–79
years who participated in annual health checkups in 1993.
The Cox proportional hazards model was used to estimate
the relative risk (RR) after adjusting for age, smoking, and
other cardiovascular risk factors. The multivariable RR (95%
confidence interval (CI)) of CVD death for positive vs negative
proteinuria was 1.38 (1.05–1.79) among men and 2.15
(1.64–2.81) among women. The respective RR for the highest
vs lowest creatinine groups (X1.3 vsp0.8 mg/dl for men and
X1.1 vs p0.6 mg/dl for women) was 1.56 (1.19–2.04) among
men and 2.15 (1.58–2.93) among women. The respective RR
for GFRo60 vs X100 ml/min/1.73 m2 was 1.65 (1.25–2.18)
among men and 1.81 (1.39–2.36) among women. For
individuals with proteinuria combined by hypercreatininemia
or reduced GFR, the risk of CVD death was two-fold higher in
men and 4–6-fold higher in women compared to those
without proteinuria and with normal creatinine level or GFR.
Similar associations were observed for stroke, coronary heart
disease, and all-cause mortality. Proteinuria, and
hypercreatininemia or reduced GFR and their combination
were significant predictors of CVD and all-cause mortality.
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Prospective studies in general populations of western
countries have indicated that proteinuria 1–5 and high serum
creatinine concentrations 6,7 were associated with increased
risk of cardiovascular disease (CVD) or all-cause mortality.
Also, glomerular filtration rate (GFR) has shown to be a
predictor for CVD events and CVD or all-cause mortality.5,8
In Asian populations, only a few studies have examined
the predictive value of proteinuria, elevated serum creatinine,
or reduced GFR for CVD events, and CVD or all-cause
mortality.9 Furthermore, these predictive values have been
assessed separately and the combined effects of these factors
have not been examined carefully. In the present study, we
evaluated serum creatinine and proteinuria as predictors of
mortality from CVD and all causes in a large prospective
cohort study of Japanese population.
RESULTS
During the 10-year follow-up, there were 7070 deaths (3933
for men and 3137 for women), comprising 985 deaths from
stroke and 536 deaths from coronary heart disease, and 1994
deaths from all CVD.
Table 1 presents the mean age and age-adjusted means and
proportions of selected risk factors at baseline, according to
the presence of proteinuria and serum creatinine levels. The
percentages of the study population with proteinuria were 3%
in men and 2% in women. The percentages of the study
population according to serum creatinine levels were as
follows: in men 23% for creatinine p0.8 mg/dl; 31% for
0.9 mg/dl; 25% for 1.0 mg/dl; 12% for 1.1 mg/dl; 5% for
1.2 mg/dl; and 3% for X1.3 mg/dl; and in women 17% for
p0.6 mg/dl; 37% for 0.7 mg/dl; 29% for 0.8 mg/dl; 11% for
0.9 mg/dl; 3% for 1.0 mg/dl; and 1% for X1.1 mg/dl. The
percentages according to estimated GFR levels were as follows:
in men 3% for GFRo60 ml/min/1.73 m2; 7% for 60–69; 21%
for 70–79; 25% for 80–89; 21% for 90–99; 23% forX100; and
in women 3% for GFR o60 ml/min/1.73 m2; 10% for 60–69;
23% for 70–79; 21% for 80–89; 25% for 90–99; 17% forX100.
Men and women with proteinuria were 2–3 years older,
and showed higher mean values of systolic and diastolic
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blood pressure (BP), serum total cholesterol, body mass
index, and the higher prevalence of current smoking and
diabetes mellitus, and lower of high density lipoprotein
(HDL)-cholesterol levels than those without proteinuria.
Compared with persons in the lowest creatinine category,
the mean age was 7-year older for men and 13-year older for
women in the highest creatinine category. Serum creatinine
levels were positively associated with systolic and diastolic BP
levels, serum total cholesterol levels, and body mass index,
and inversely associated with HDL-cholesterol levels. Serum
creatinine levels were also positively associated with the
proportions of antihypertensive medication use, current
smokers, and diabetes mellitus for both men and women,
and inversely associated with alcohol intake for men.
Table 2 presents the relative risks (RRs) of deaths from
stroke, coronary heart disease, CVD, non-CVD, and all causes
according to the presence of proteinuria and serum creatinine
levels. Compared with persons without proteinuria, those
with proteinuria had 1.8–2.9-fold higher age-adjusted risks of
mortality from coronary heart disease, CVD, non-CVD, and
all causes for both men and women, and from stroke for
women. Except for stroke, these excess risks of mortality were
statistically significant after further adjustment for cardio-
vascular risk factors.
The age-adjusted risk of mortality was 1.3–2.5-fold higher
for stroke, CVD, and all causes among both men and women
with the highest creatinine category than those with the
lowest category. The age-adjusted risk of mortality from
coronary heart disease was 1.9-fold higher for women.
Further adjustment for cardiovascular risk factors and
proteinuria attenuated these relations, but they remained
statistically significant for stroke, CVD, and all-cause
mortality in both sexes. We also found excess risks of
mortality from CVD in the second highest creatinine
category (1.0 mg/dl) for women. The association between
serum creatinine and risk of mortality from non-CVD was
generally weak, but the excess risk of mortality was found in
the highest creatinine category for both men and women.
Table 3 presents the RRs of deaths from stroke, coronary
heart disease, CVD, non-CVD, and all causes according to
GFR levels. For both men and women, the age-adjusted risk
of mortality was 1.3–2.1-fold higher for stroke, CVD, and all
causes among persons with the lowest GFR category
(o60 ml/min/1.73 m2) than those with the highest GFR
category (X100 ml/min/1.73 m2). Further adjustment for
cardiovascular risk factors and proteinuria attenuated these
relations, but they remained statistically significant for stroke,
CVD, and all-cause mortality in both sexes.
Table 1 | Age-adjusted mean values or prevalence (%) of risk factors at baseline according to urinary protein and serum
creatinine levels in men and women aged 40–79 years
Urinary protein Serum creatinine, mg/dl (mmol/l)
 + or more p0.8 (71) 0.9 (80) 1.0 (89) 1.1 (97) 1.2 (106) X1.3 (115) P for trend
Men
No. 29 492 926 7213 9630 7739 3822 1443 917
Age (years) 60.5 62.7*** 59.7 59.7 60.5*** 62.2*** 64.0*** 67.1*** o0.001
Systolic blood pressure (mmHg) 136.0 144.2*** 136.1 136.4 136.1 136.2 137.5** 137.9** o0.001
Diastolic blood pressure (mmHg) 80.8 84.8*** 80.2 80.8*** 81.0*** 81.6*** 82.4*** 82.5*** o0.001
Antihypertensive medication use (%) 19.0 31.4*** 15.9 17.7** 19.4*** 22.3*** 29.9*** 37.8*** o0.001
Serum total cholesterol (mg/dl) 192.2 200.3*** 188.6 191.4*** 193.8*** 195.8*** 198.1*** 198.1*** o0.001
HDL-cholesterol (mg/dl) 52.0 50.6** 55.1 52.3*** 51.1*** 49.8*** 48.0*** 47.0*** o0.001
Body mass index (kg/m2) 23.3 24.2*** 22.6 23.2*** 23.5*** 23.9*** 24.3*** 24.4*** o0.001
Current smoker (%) 51.2 55.7** 56.9 52.7*** 49.1*** 47.3*** 43.7*** 43.1*** o0.001
Alcohol (g/day) 22.0 23.8* 26.4 22.7*** 20.5*** 18.5*** 16.6*** 15.1*** o0.001
Diabetes (%) 8.3 18.4*** 7.7 8.3 9.2*** 9.3** 9.5* 12.8*** o0.001
 + or more p0.6 (53) 0.7 (62) 0.8 (71) 0.9 (80) 1.0 (89) X1.1 (97) P for Trend
Women
No. 58 942 1003 10 554 22 791 17 893 6847 1707 876
Age (years) 58.1 61.5*** 55.2 56.7*** 59.0*** 61.9*** 64.9*** 68.0*** o0.001
Systolic blood pressure (mmHg) 131.6 139.6*** 131.3 131.6 131.8* 132.2*** 132.4* 133.2** o0.001
Diastolic blood pressure (mmHg) 77.6 82.0*** 76.9 77.6*** 78.0*** 78.2*** 78.2*** 78.4*** o0.001
Antihypertensive medication use (%) 19.0 34.0*** 15.0 16.8*** 20.2*** 24.5*** 35.4*** 40.5*** o0.001
Serum total cholesterol (mg/dl) 206.8 215.2*** 203.0 206.3*** 208.7*** 209.8*** 208.7*** 206.4** o0.001
HDL-cholesterol (mg/dl) 56.4 55.0** 56.7 56.7 56.4 55.7*** 54.9*** 54.1*** o0.001
Body mass index (kg/m2) 23.6 24.8*** 23.4 23.5*** 23.6*** 23.8*** 24.1*** 24.2*** o0.001
Current smoker (%) 4.8 6.9** 5.0 4.4* 5.0 5.2 6.1* 8.0*** o0.001
Alcohol (g/day) 1.3 1.0 1.2 1.3 1.3 1.2 1.0 1.3 0.20
Diabetes (%) 4.4 14.6*** 4.0 4.2 4.7** 5.7*** 6.9*** 8.3*** o0.001
*Po0.05; **Po0.01; ***Po0.001; difference from the lowest creatinine category, urinary protein negative category.
P for trend are for the multiple regression analysis of serum creatinine level adjusted for age.
HDL: high density lipoprotein.
Kidney International (2006) 69, 1264–1271 1265
F Irie et al.: Creatinine, proteinuria and CVD in Japanese population o r i g i n a l a r t i c l e
Table 4 presents the RRs of death from CVD and all causes
according to the combination of the presence of proteinuria
with creatinine and GFR categories. Men and women with
either proteinuria or hypercreatininemia had 1.3–2.4-fold
higher age-adjusted risks of mortality from CVD and all
causes. Men with both proteinuria and hypercreatininemia
had 2.7–2.8-fold higher age-adjusted risks of mortality from
CVD and all causes, while women with the same abnormality
had 4.8–7.0-fold higher risks of mortality from CVD and all
causes. These relations did not change substantially after
adjustment for cardiovascular risk factors.
Men and women with either proteinuria or reduced GFR
had 1.3–2.5-fold higher age-adjusted risks of mortality from
CVD and all causes. Men with both proteinuria and reduced
GFR had 2.6–2.8-fold higher age-adjusted risks of mortality
from CVD and all causes, while women with the same
abnormality had 3.3–5.0-fold higher risks of mortality from
CVD and all causes. These relations did not change
substantially after adjustment for cardiovascular risk factors.
There were no significant interactions of proteinuria with
creatinine or GFR category (P for interaction 40.10).
The population attributable risk percent of proteinuria
was 1.3% in men and 2.0% in women for CVD, and 1.8% in
men and 1.4% in women for all causes. The population
attributable risk percent of reduced GFR was 1.4% in men
and 2.2% in women for CVD, and 1.1% in men and 1.5% in
women for all causes.
DISCUSSION
In this large prospective study of Japanese general popula-
tions, we found that proteinuria, high serum creatinine
concentrations, and reduced GFR were associated with
increased risk of mortality from CVD and all causes in both
men and women. Previous studies have shown that the
multivariable RRs of CVD and all-cause mortality for
proteinuria ranged from 1.2 to 2.9.1–5 The respective relative
risks of CVD and all-cause mortality for hypercreatinemia or
reduced GFR ranged from 1.3 to 1.7.5–8 The magnitudes of
those associations with proteinuria, elevated serum creatinine
concentrations, and GFR in the present study were similar to
those in previous studies. Furthermore, the present study
showed that proteinuria was significantly associated with risk
of deaths from coronary heart disease and that elevated
serum creatinine or reduced GFR was an independent
predictor for stroke mortality in both sexes.
The mechanisms for the associations of proteinuria and
elevated serum creatinine with mortality warrant discussion.
First, these abnormalities may be surrogate markers for
generalized vascular damage as well as renal dysfunction,
which raises risk of mortality from CVD as well as all causes.
For example, albuminuria may be a marker of widespread
vascular abnormalities, including those of the glomerular
capillary wall.10 Another explanation may be that renal
dysfunction may enhance intermediate risk factors such as
hypertension,11 hyperhomocysteinemia,12,13 and abnormali-
ties of thrombogenic factors.14,15
A unique finding of the present study is that the
combination of proteinuria with hypercreatinemia or re-
duced GFR was associated with a substantial increase in risk
of mortality for both men and women, although a synergic
effect of proteinuria on hypercreatininemia or reduced GFR
was not observed. Recent prospective studies have shown that
proteinuria is not only a risk factor of CVD but also a strong
predictor of end-stage renal disease in general popula-
tions.16,17 Individuals with proteinuria combined by hyper-
creatininemia or reduced GFR may be in a course of a rapid
decline in renal function, compared with those without these
disorders. Progressive renal dysfunction may aggravate
intermediate risk factors mentioned above, leading to the
increased risk of mortality.
Although the mechanisms linking these markers of kidney
damage to the excess risk of death from CVD require further
study, the public health implications of our results seem
indisputable. Early detection and treatment of chronic kidney
disease may reduce the social burden of cardiovascular
disease. In 1998, the National Kidney Foundation Task Force
on Cardiovascular Disease in Chronic Renal Disease issued a
report emphasizing the high risk of CVD in chronic kidney
disease and recommended that patients with such diseases be
considered in the ‘highest risk group’ for subsequent CVD
events.18 In 2003, the American Heart Association issued a
statement that reinforced the recommendation of the
National Kidney Foundation Task Force.19
Our study has several limitations. First, the subjects of this
study were participants of a health checkup for residents with
approximately 40% response rate. However, the potential
selection bias may be small since the rate of all-cause
mortality did not differ between the study subjects and the
total Japanese population. The standard mortality ratio
(SMR) of all-cause mortality among the study participants
was 95 (95% confidence interval (CI): 86–103) for men and
100 (95% CI: 89–110) for women compared with the total
Japanese population in 2000.20,21 Second, we did not have the
incidence data. We used the dates on the death certificates
and did not examine the stroke subtypes. However, previous
studies have shown that the diagnosis on death certificate
with regard to stroke subtypes is valid due to the high use of
Computed Tomography scan and magnetic resonance
imaging in hospitals in Japan.22,23 Third, the dipstick
provides only a semiquantitative measurement of protein-
uria. The dipstick is relatively insensitive and does not register
as positive until total protein excretion is more than 300 mg/
day. Additionally, GFR estimated from serum creatinine
levels is not so accurate measure of renal function as actual
GFR measurements by using inulin or 125I-iothalamate.
However, such a test is not feasible for general populations.
In conclusion, proteinuria, elevated serum creatinine and
reduced GFR were significant predictors for CVD and all-
cause mortality in the Japanese population and the
combination of proteinuria with hypercreatininemia or
reduced GFR was associated with a substantial increase in
mortality.
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Table 2 | Relative risks and 95% confidence intervals of mortality relative to negative urinary protein and the lowest creatinine
category in men and women aged 40–79 years




0.9 (80) 1.0 (89) 1.1 (97) 1.2 (106) X1.3 (115)
RR 95% CI RR 95% CI RR 95% CI RR 95% CI RR 95% CI RR 95% CI
Men
Number at risk 29 492 926 7213 9630 7739 3822 1443 917
Stroke
No. of deaths 450 23 94 134 117 63 39 44
Age-adjusted RR 1.00 1.42 (0.93–2.15) 1.00 1.00 (0.77–1.30) 0.98 (0.74–1.28) 0.91 (0.66–1.26) 1.28 (0.88–1.86) 1.86 (1.29–2.67)
Multivariable RRa 1.00 1.10 (0.71–1.68) 1.00 1.02 (0.78–1.33) 1.03 (0.78–1.35) 0.97 (0.70–1.35) 1.32 (0.90–1.94) 1.90 (1.30–2.77)
Coronary heart disease
No. of death 259 26 57 76 64 57 22 18
Age-adjusted RR 1.00 2.90 (1.94–4.34) 1.00 0.96 (0.68–1.35) 0.94 (0.65–1.34) 1.51 (1.04–2.18) 1.37 (0.83–2.24) 1.54 (0.90–2.62)
Multivariable RRa 1.00 1.96 (1.29–2.97) 1.00 0.87 (0.62–1.23) 0.83 (0.58–1.19) 1.25 (0.84–1.82) 1.01 (0.61–1.67) 1.00 (0.57–1.73)
All cardiovascular disease
No. of deaths 923 61 196 265 236 157 80 82
Age-adjusted RR 1.00 1.86 (1.44–2.41) 1.00 0.96 (0.79–1.15) 0.97 (0.80–1.17) 1.13 (0.92–1.40) 1.32 (1.02–1.72) 1.79 (1.38–2.32)
Multivariable RRa 1.00 1.38 (1.05–1.79) 1.00 0.95 (0.79–1.14) 0.97 (0.80–1.18) 1.12 (0.90–1.39) 1.24 (0.95–1.62) 1.56 (1.19–2.04)
Non-cardiovascular disease
No. of deaths 2701 162 705 824 701 368 149 170
Age-adjusted RR 1.00 1.77 (1.51–2.07) 1.00 0.84 (0.76–0.93) 0.83 (0.75–0.92) 0.79 (0.69–0.89) 0.75 (0.63–0.89) 1.18 (0.99–1.39)
Multivariable RRa 1.00 1.64 (1.39–1.93) 1.00 0.88 (0.79–0.97) 0.88 (0.79–0.98) 0.85 (0.75–0.97) 0.81 (0.67–0.97) 1.19 (1.00–1.42)
All causes
No. of deaths 3624 223 901 1089 937 525 229 252
Age-adjusted RR 1.00 1.79 (1.57–2.05) 1.00 0.87 (0.79–0.95) 0.86 (0.78–0.94) 0.87 (0.78–0.96) 0.88 (0.76–1.02) 1.32 (1.15–1.52)
Multivariable RRa 1.00 1.56 (1.36–1.80) 1.00 0.89 (0.82–0.98) 0.90 (0.82–0.99) 0.91 (0.82–1.02) 0.92 (0.79–1.06) 1.29 (1.11–1.49)
+ or more 0.7 (62) 0.8 (71) 0.9 (80) 1.0 (89) X1.1 (97)
 RR 95% CI p0.6 (53) RR 95% CI RR 95% CI RR 95% CI RR 95% CI RR 95% CI
Women
Number at risk 58 942 1003 10 554 22 791 17 893 6847 1707 876
Stroke
No. of deaths 460 19 53 153 141 71 38 38
Age-adjusted RR 1.00 1.79 (1.13–2.83) 1.00 1.13 (0.83–1.54) 1.03 (0.75–1.42) 1.01 (0.71–1.44) 1.61 (1.06–2.45) 2.53 (1.65–3.86)
Multivariable RRa 1.00 1.36 (0.85–2.17) 1.00 1.16 (0.85–1.59) 1.05 (0.76–1.44) 0.98 (0.68–1.40) 1.47 (0.96–2.25) 2.26 (1.47–3.47)
Coronary heart disease
No. of deaths 214 22 32 67 73 38 15 17
Age-adjusted RR 1.00 4.54 (2.93–7.04) 1.00 0.82 (0.54–1.25) 0.89 (0.59–1.36) 0.91 (0.57–1.46) 1.08 (0.58–2.00) 1.94 (1.07–3.53)
Multivariable RRa 1.00 3.08 (1.95–4.87) 1.00 0.82 (0.54–1.26) 0.86 (0.56–1.31) 0.81 (0.50–1.31) 0.84 (0.45–1.57) 1.45 (0.79–2.68)
All cardiovascular disease
No. of deaths 889 59 102 288 289 148 77 74
Age-adjusted RR 1.00 2.87 (2.20–3.73) 1.00 1.10 (0.88–1.38) 1.10 (0.87–1.37) 1.09 (0.84–1.40) 1.68 (1.24–2.26) 2.53 (1.87–3.43)
Multivariable RRa 1.00 2.15 (1.64–2.81) 1.00 1.13 (0.90–1.42) 1.10 (0.88–1.38) 1.04 (0.80–1.34) 1.49 (1.10–2.01) 2.15 (1.58–2.93)
Non-cardiovascular disease
No. of deaths 2035 76 314 695 634 302 103 111
Age-adjusted RR 1.00 1.79 (1.42–2.25) 1.00 0.91 (0.80–1.04) 0.88 (0.77–1.01) 0.88 (0.75–1.03) 0.97 (0.78–1.22) 1.77 (1.42–2.20)
Multivariable RRa 1.00 1.59 (1.26–2.01) 1.00 0.93 (0.82–1.07) 0.90 (0.79–1.03) 0.89 (0.75–1.04) 0.95 (0.76–1.19) 1.61 (1.29–2.02)
All causes
No. of death 2924 135 416 983 923 450 180 185
Age-adjusted RR 1.00 2.14 (1.80–2.55) 1.00 0.96 (0.85–1.07) 0.93 (0.83–1.05) 0.93 (0.81–1.07) 1.18 (0.98–1.40) 2.00 (1.67–2.38)
Multivariable RRa 1.00 1.79 (1.52–2.17) 1.00 0.98 (0.87–1.10) 0.95 (0.85–1.07) 0.92 (0.81–1.06) 1.11 (0.93–1.33) 1.78 (1.49–2.13)
RR: relative risk; CI: confidence interval.
aAdjusted for age, hypertension category, cigarette smoking, alcohol intake, diabetes mellitus, sex-specific quintiles of serum total cholesterol level, serum HDL-cholesterol
level and body mass index, and either serum creatinine or urinary protein.
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Table 3 | Relative risks and 95% confidence intervals of mortality relative to the highest GFR category in men and women aged
40–79 years
GFR (ml/min/1.73 m2)
o60 60–69 70–79 80–89 90–99
X100
RR 95% CI RR 95% CI RR 95% CI RR 95% CI RR 95% CI
Men
Number at risk 824 2023 6540 7738 6557 7082
Stroke
No. of deaths 44 68 127 126 42 84
Age-adjusted RR 1.93 (1.33–2.80) 1.15 (0.82–1.60) 0.95 (0.72–1.25) 1.05 (0.80–1.39) 1.02 (0.70–1.48) 1.00
Multivariable RRa 1.98 (1.34–2.92) 1.22 (0.87–1.71) 1.01 (0.76–1.34) 1.09 (0.82–1.44) 1.06 (0.73–1.54) 1.00
Coronary heart disease
No. of deaths 18 46 80 57 43 50
Age-adjusted RR 1.68 (0.97–2.90) 1.71 (1.13–2.59) 1.15 (0.80–1.64) 0.88 (0.60–1.29) 1.45 (0.95–2.19) 1.00
Multivariable RRa 1.08 (0.61–1.89) 1.31 (0.85–2.00) 1.00 (0.69–1.43) 0.78 (0.53–1.14) 1.38 (0.91–2.10) 1.00
All cardiovascular disease
No. of deaths 82 150 274 231 104 175
Age-adjusted RR 1.88 (1.44–2.46) 1.35 (1.07–1.69) 1.03 (0.85–1.25) 0.96 (0.79–1.17) 1.13 (0.88–1.45) 1.00
Multivariable RRa 1.65 (1.25–2.18) 1.29 (1.03–1.63) 1.04 (0.85–1.26) 0.95 (0.78–1.17) 1.15 (0.89–1.47) 1.00
Non-cardiovascular disease
No. of deaths 165 288 741 713 353 657
Age-adjusted RR 1.17 (0.98–1.39) 0.81 (0.70–0.94) 0.81 (0.73–0.90) 0.84 (0.75–0.93) 0.91 (0.79–1.03) 1.00
Multivariable RRa 1.19 (1.00–1.43) 0.87 (0.75–1.01) 0.87 (0.78–0.97) 0.88 (0.79–0.98) 0.93 (0.82–1.07) 1.00
All causes
No. of deaths 247 438 1015 944 457 832
Age-adjusted RR 1.33 (1.15–1.54) 0.94 (0.83–1.06) 0.86 (0.78–0.94) 0.86 (0.79–0.95) 0.95 (0.85–1.07) 1.00
Multivariable RRa 1.31 (1.12–1.52) 0.98 (0.86–1.10) 0.91 (0.82–1.00) 0.90 (0.82–0.99) 0.98 (0.87–1.10) 1.00
o60 60–69 70–79 80–89 90–99
RR 95% CI RR 95% CI RR 95% CI RR 95% CI RR 95% CI X100
Women
Number at risk 2073 6167 13 921 12 664 15 289 10 554
Stroke
No. of deaths 76 70 139 133 23 53
Age-adjusted RR 2.04 (1.42–2.92) 1.00 (0.69–1.43) 1.04 (0.76–1.43) 1.16 (0.84–1.60) 1.00 (0.60–1.68) 1.00
Multivariable RRa 1.85 (1.28–2.67) 0.97 (0.67–1.39) 1.05 (0.77–1.45) 1.20 (0.87–1.65) 1.00 (0.59–1.67) 1.00
Coronary heart disease
No. of deaths 32 37 72 58 11 32
Age-adjusted RR 1.47 (0.89–2.43) 0.89 (0.55–1.43) 0.90 (0.59–1.37) 0.85 (0.55–1.31) 0.74 (0.36–1.52) 1.00
Multivariable RRa 1.13 (0.67–1.89) 0.79 (0.49–1.28) 0.87 (0.57–1.32) 0.86 (0.55–1.32) 0.72 (0.35–1.48) 1.00
All cardiovascular disease
No. of deaths 150 146 286 253 41 102
Age-adjusted RR 2.08 (1.60–2.69) 1.07 (0.83–1.39) 1.11 (0.88–1.39) 1.14 (0.90–1.44) 0.94 (0.64–1.38) 1.00
Multivariable RRa 1.81 (1.39–2.36) 1.03 (0.79–1.33) 1.12 (0.89–1.40) 1.17 (0.93–1.48) 0.93 (0.63–1.36) 1.00
Non-cardiovascular disease
No. of deaths 203 304 608 518 212 314
Age-adjusted RR 1.27 (1.06–1.52) 0.88 (0.75–1.04) 0.88 (0.77–1.01) 0.91 (0.79–1.04) 0.91 (0.76–1.10) 1.00
Multivariable RRa 1.21 (1.00–1.45) 0.89 (0.76–1.05) 0.91 (0.79–1.04) 0.93 (0.80–1.07) 0.93 (0.77–1.11) 1.00
All causes
No. of deaths 353 450 894 771 253 416
Age-adjusted RR 1.51 (1.30–1.74) 0.93 (0.81–1.06) 0.94 (0.83–1.05) 0.96 (0.85–1.09) 0.95 (0.80–1.11) 1.00
Multivariable RRa 1.39 (1.20–1.62) 0.92 (0.80–1.06) 0.96 (0.85–1.08) 0.99 (0.87–1.11) 0.95 (0.81–1.12) 1.00
RR, relative risk, CI, confidence interval; GFR, glomerular filtration rate.
aAdjusted for age, hypertension category, cigarette smoking, alcohol intake, diabetes mellitus, sex-specific quintiles of serum total cholesterol level, serum HDL-cholesterol
level and body mass index, and urinary protein.
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MATERIALS AND METHODS
Study population
The population surveyed included a total of 96 739 persons (32 904
men and 63 835 women) aged 40–79 years living in Ibaraki
prefecture who participated in annual community-based health
checkups in 1993. A total of 38 out of 85 communities in Ibaraki,
Japan, were included in the present study. The participation rate of
health checkups was 36.4% in the study areas, and was similar to
35.8% in Ibaraki prefecture in 1993. The study population consisted
3% of the census population living in Ibaraki prefecture. Persons
with a history of stroke (n¼ 958), heart disease (n¼ 4503), and
kidney disease (n¼ 504) were excluded from the study, and the data
of 91 432 persons (30 764 men and 60 668 women) were used for the
analysis. The study protocol was approved by the Ethics Committee
of Ibaraki Prefectural Office.
Mortality surveillance
Mortality surveillance was conducted with systematic review of the
death certificates and resident registration in cooperation with
public health centers and municipal government offices. The
underlying causes of death were coded according to the Interna-
tional Classification of Diseases, 9th revision (ICD-9, 1993–1994)
and 10th revision (ICD-10, 1995–2003). The follow-up was
conducted until the end of 2003. Only 2984 (3.3%) persons moved
out of the communities during the follow-up, and 7070 (7.7%)
persons died. Such individuals were censored at the date of moving
out or death. The average follow-up period for all participants was
10.1 years.
Cause-specific mortality was also determined by stroke (ICD-9
codes 430–438; ICD-10 codes I60-I69), coronary heart disease (codes
410–414; I20-I25), all cardiovascular disease (codes 393–459;
I00-I99), and non-cardiovascular disease (codes 001–392, 460–999;
A00-H95, J00-Y89), separately.
Measurement of risk factors
Urinary protein and serum creatinine and other cardiovascular risk
factors were measured at baseline survey when the participants were
examined in 1993. Serum creatinine was measured by the modified
method of Jaffe’s reaction using the automated analyzer (RX-30,
Nihon Denshi Inc., Tokyo, Japan). GFR was estimated by using the
abbreviated equation developed at Cleveland Clinic laboratory for
the Modification of Diet in Renal Disease (MDRD) Study as follows:
GFR (ml/min/1.73 m2)¼ 186.3 age0.203 serum creatinine
level1.154 ( 0.742 if female) (1.212 if black subject).24,25 Urinary
protein was checked by dipstick urinalysis (Ames Hemacombisticks,
Bayer-Sankyo, Tokyo). Trace-positive sample of proteinuria was re-
examined using the sulfosalicylic acid test, and was divided into four
groups (, 1þ , 2þ , 3þ ). The result of ‘1þ ’ or more was regarded
as proteinuria.
We measured several potential confounders: serum total choles-
terol, serum HDL-cholesterol, plasma glucose level, blood pressure,
use of antihypertensive medication, body mass index, cigarette
Table 4 | Relative risks and 95% confidence intervals of mortality from all CVD and all causes relative to negative urinary
protein and the lowest creatinine category or relative to negative urinary protein and GFRX60 ml/min/1.73 m2 category in
men and women aged 40–79 years
Creatinine and urinary protein categories GFR and urinary protein categories
Urinary protein 
+ or more  + or more
Urinary protein 





RR 95% CI RR 95% CI RR 95% CI
GFR, ml/min/
1.73 m2 RR 95% CI RR 95% CI RR 95% CI
Men
Number at risk 28 731 792 761 134 28 812 804 680 122
All CVD
No. of deaths 859 46 64 15 859 46 64 15
Age-adjusted RR 1.00 1.74 (1.30–2.34) 1.64 (1.27–2.12) 2.75 (1.65–4.59) 1.00 1.74 (1.29–2.34) 1.66 (1.29–2.15) 2.79 (1.68–4.66)
Multivariable RRa 1.00 1.40 (1.03–1.88) 1.51 (1.16–1.96) 2.12 (1.27–3.55) 1.00 1.39 (1.03–1.88) 1.53 (1.18–1.98) 2.15 (1.28–3.60)
P for interaction 0.99 0.99
All causes
No. of deaths 3437 169 187 54 3440 171 184 52
Age-adjusted RR 1.00 1.65 (1.41–1.92) 1.32 (1.14–1.53) 2.69 (2.06–3.52) 1.00 1.66 (1.42–1.94) 1.32 (1.14–1.54) 2.64 (2.01–3.48)
Multivariable RRa 1.00 1.49 (1.28–1.74) 1.33 (1.14–1.54) 2.49 (1.90–3.26) 1.00 1.50 (1.29–1.76) 1.33 (1.14–1.55) 2.44 (1.85–3.21)
P for interaction 0.23 0.31
Women
Number at risk 58 191 898 751 105 57 068 839 1874 164
All CVD
No. of deaths 835 42 54 17 766 36 123 23
Age-adjusted RR 1.00 2.40 (1.76–3.27) 1.87 (1.42–2.47) 7.03 (4.35–11.37) 1.00 2.45 (1.75–3.42) 1.72 (1.42–2.09) 5.00 (3.30–7.58)
Multivariable RRa 1.00 1.96 (1.43–2.68) 1.71 (1.29–2.26) 5.73 (3.52–9.34) 1.00 2.02 (1.44–2.83) 1.58 (1.30–1.93) 4.00 (2.62–6.10)
P for interaction 0.11 0.47
All causes
No. of deaths 2780 101 144 34 2626 90 298 45
Age-adjusted RR 1.00 1.86 (1.53–2.27) 1.83 (1.54–2.16) 4.80 (3.42–6.73) 1.00 1.91 (1.55–2.35) 1.47 (1.30–1.66) 3.34 (2.49–4.49)
Multivariable RRa 1.00 1.69 (1.38–2.06) 1.71 (1.44–2.03) 4.09 (2.90–5.77) 1.00 1.74 (1.40–2.14) 1.40 (1.24–1.58) 2.89 (2.14–3.89)
P for interaction 0.13 0.42
RR: relative risk, CI: confidence interval; GFR: glomerular filtration rate
Creatinine category: low (o1.3 mg/dl in men and o1.1 mg/dl in women) and high (X1.3 mg/dl in men and X1.1 mg/dl in women).
aAdjusted for age, hypertension category, cigarette smoking, alcohol intake, diabetes mellitus, sex-specific quintiles of serum total cholesterol level, serum HDL-cholesterol
level, and body mass index.
Kidney International (2006) 69, 1264–1271 1269
F Irie et al.: Creatinine, proteinuria and CVD in Japanese population o r i g i n a l a r t i c l e
smoking, usual alcohol intake, history of kidney disease, and diabetes
mellitus. Serum total cholesterol was measured by an enzyme
method using an RX-30 device (Nihon Denshi Inc., Tokyo, Japan).
HDL-cholesterol was measured with a phosphotungestic acid
magnesium method using an MTP-32 device (Corona Electric,
Ibaraki, Japan). The measurement of these lipids in the laboratory of
Ibaraki Health Service Association was standardized by the
laboratory of the Osaka Medical Center for Health Science and
Promotion under the laboratory network program of the US Centers
for Disease Control and Prevention (Atlanta, GA, USA).26 Plasma
glucose levels were measured using a glucose oxidase electrode
method with a GA1140 device (Kyoto Daiichi Kagaku, Kyoto, Japan).
Diabetes was determined by a plasma glucose level of X126 mg/dl
fasting, X200 mg/dl in non-fasting, or with treatment of diabetes
mellitus. BP was measured by trained observers using standard
mercury sphygmomanometer on the right arm of seated participants
who had rested for 5 min. Height in stocking feet and weight in light
clothing were measured. body mass index was calculated as weight
(kg) divided by the square of height (m). An interview was
conducted to ascertain the number of cigarettes smoked per day,
usual weekly intake of alcohol, which was converted to grams of
ethanol per day, and histories of stroke, heart, and kidney diseases.
Statistical analysis
Differences in age-adjusted mean values and the prevalence of
potential confounding factors between two categories of urinary
protein (, þ or more) and among six categories of serum
creatinine levels (p0.8, 0.9, 1.0, 1.1, 1.2, X1.3 mg/dl for men, and
p0.6, 0.7, 0.8, 0.9, 1.0, X1.1 mg/dl for women) were tested by the
analysis of covariance and w2 test, respectively. When
the overall difference was significant (Po0.05), we compared
confounding factors between the lowest category and the other
categories of creatinine levels. The relative risk of death and its 95%
confidence interval (CI) were calculated with reference to the risk
for persons with creatinine levelp0.8 mg/dl in men andp0.6 mg/dl
in women. Participants were stratified into six categories of GFR
levels (o60, 60–79, 70–79, 80–89, 90–99,X100 ml/min/1.73 m2) and
the RR and its 95% CI of death were also calculated with reference to
the risk for persons with GFR level X100 ml/min/1.73 m2 in both
men and women. These estimates were adjusted for age and other
potential confounding factors using the Cox proportional hazards
model. Potential confounding factors were hypertension category
(normal BP, high-normal BP, grade 1 hypertension (mild), grade 2
hypertension (moderate), grade 3 hypertension (severe)),27 anti-
hypertensive treatment (yes vs no), cigarette smoking (never-
smokers, ex-smokers, current 1–19, 20–29, and X30 no./day),
diabetes mellitus (fasting blood glucose X126 mg/dl or non-fasting
blood glucose X200 mg/dl or treatment for diabetes), usual alcohol
intake (never, former, current o56 g/day, and X56 g/day in
ethanol), sex-specific quintiles of body mass index , serum total
cholesterol, and serum HDL-cholesterol.
The analysis was also conducted according to the combination of
the presence of proteinuria with serum creatinine category (o1.3,
X1.3 mg/dl for men and o1.1, X1.1 mg/dl for women) and GFR
category (o60, X60 ml/min/1.73 m2). The significance of the
interaction for serum creatinine and GFR were tested in the
multivariable models using the interaction terms of urinary protein
(, þ or more) creatinine category and urinary proteinGFR
category, respectively.
Furthermore, gender-specific population attributable risks of
reduced GFR or proteinuria were calculated as follows:28 population
attributable risk ¼ p(RR1)/(p(RR1)þ 1), where p is the
proportion of the population that is exposed, and RR is the relative
risk of population that is exposed. The relative risks were calculated
with reference to the risk for persons with GFRX60 ml/min/1.73 m2
and for those with proteinuria (þ or more) for both sexes. All
statistical analyses were conducted using SAS, version 8.02 (SAS
Institute, Inc., Cary, NC, USA).
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